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The mechanisms of ultra-low dose opioid
agonist-antagonistThe major drawback of PCA for postoperative pain
management is opioid related side effects, such as nausea,
vomiting and pruritis etc, which discourage patients’ use of
PCA. Therefore, reduction of the opioid related side effect
during PCA using is a major issue to improve the quality.
Combination various adjuvant with morphine in PCA
regimen to reduce the dose of morphine and thus decrease
the incidence and severity of morphine related side effect
is frequently used. Article published in JFMA (2009; 118)
found that combination of low-dose nalbuphine and
morphine in PCA decreases the incidence of opioid-related
nausea without affecting the analgesia and PCA require-
ment and concluded this combination improving the quality
of PCA with less incidence of nausea in postoperative pain
control.1 They suggested that the mechanism might be
similar to the effect of ultra low dose naloxone, which
improves the analgesic effect of morphine by inhibiting the
excitatory action of morphine.2 As known, combination of
adjuvant with morphine administration in pain manage-
ment reduces the morphine related side effects the main
mechanism is the morphine spare effect. In this article,
small dose nalbuphine, a mixed kappa opioid agonist and
mu-opioid antagonist, inhibited the action of morphine on
mu-opioid receptor induced side effects, which may also
antagonize the analgesic effect of morphine, however, the
partial kappa opioid receptor antagonist effect may restore
the morphine analgesia. However, in this article, authors
failed to observe the morphine sparing effect, lesser dose
of morphine and better VAS pain score, by the small dose
nalbuphin coadministration.
As discussed by author, the mechanism of ultra low dose
naloxone in enhancing of morphine’s analgesic effect is due
to antagonize the excitatory effect of morphine, however, it
was failed to demonstrate in clinical patient pain manage-
ment. In our recent animal studies, we found that ultra
low dose naloxone cotreatment with morphine can inhibit
neuropathic thermal hyperalgesia3 and morphine tolerance
as well,4 which might be through its antiinflammtory action
in the spinal cord glia andmoreover, ultra low dose naloxone0929-6646/$ - see front matter Copyright ª 2011, Elsevier Taiwan LLC
doi:10.1016/j.jfma.2011.08.013can reinitiate the classical mu-opioid receptor and Gi-
protein coupling in the pertussis toxin induced neuro-
pathic pain animals.5 Therefore, reduction of the incidence
of nausea in this article may be just simply the nalbuphine
binding to the mu-opioid receptors, and possibly less
reduction of morphine’s analgesic effect which however
was restored by the partial agonist property of kappa opioid
receptor of nalbuphine.
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